Effectiveness of injectable risperidone long-acting therapy for schizophrenia: Data from the US, Spain, Australia, and Belgium

Annals of General Psychiatry

Volumn 10, Issue , 2011, Pages

  Lambert, Tim ^a   Olivares, José M ^b   Peuskens, Joseph ^c   DeSouza, Cherilyn ^d   Kozma, Chris M ^e   Otten, Patrick ^f   Crivera, Concetta ^g   Jacobs, An ^h   Macfadden, Wayne ^g   Mao, Lian ⁱ   Rodriguez, Stephen C ^g   Dirani, Riad ^g   Akhras, Kasem S ⁱ  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTH CAROLINA   (United States)

^f SGS Medisearch International NV   (Belgium)

^g JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^h JOHNSON AND JOHNSON   (United States)

ⁱ JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LONG ACTING DRUG; RISPERIDONE;

ADULT; ARTICLE; AUSTRALIA; BELGIUM; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SCHIZOPHRENIA; SPAIN; TREATMENT OUTCOME; UNITED STATES;

EID: 79953255417     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-10-10     Document Type: Article

References (30)

1. World Health Organization World Mental Health Atlas 2005, Geneva, Switzerland: WHO, World Health Organization.
2. Eli Lilly and Company Keeping care complete: a caregivers' perspective on mental illness and wellness. An international survey 2010, Indianapolis, IN: Eli Lilly and Company, Eli Lilly and Company.
3. Eli Lilly and Company Keeping care complete: a physicians' perspective on mental illness and wellness. An international survey: International findings sheet 2010, Indianapolis, IN: Eli Lilly and Company, Eli Lilly and Company.
4. Zhu B, Ascher-Svanum H, Faries DE, Peng X, Salkever D, Slade EP. Costs of treating patients with schizophrenia who have illness-related crisis events. BMC Psychiatry 2008, 8:72. 10.1186/1471-244X-8-72, 2533651, 18727831.
5. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909. 10.4088/JCP.v63n1007, 12416599.
6. Docherty JP, Grogg AL, Kozma C, Mahmoud R. Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. Presented at The American College of Neuropsychopharmacology 41st Annual Meeting 2002, San Juan, Puerto Rico.
7. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004, 161:692-699. 10.1176/appi.ajp.161.4.692, 15056516.
8. Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002, 40:630-639. 10.1097/00005650-200208000-00002, 12187177.
9. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004, 55:886-891. 10.1176/appi.ps.55.8.886, 15292538.
10. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006, 67:453-460. 10.4088/JCP.v67n0317, 16649833.
11. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007, 23:2305-2312. 10.1185/030079907X226050, 17697454.
12. Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997, 17:205-229. 10.1016/S0893-133X(97)00045-6, 9326746.
13. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindstrøm E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998, 8:55-66. 10.1016/S0924-977X(97)00045-X, 9452941.
14. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003, 64:14-17. 10.4088/JCP.v64n0105, 14680414.
15. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003, 160:1125-1132. 10.1176/appi.ajp.160.6.1125, 12777271.
16. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, Pretorius H, David AS. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005, 15:111-117. 10.1016/j.euroneuro.2004.07.003, 15572280.
17. Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, Rodriguez S, Gharabawi GM. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2006, 67:1194-1203. 10.4088/JCP.v67n0804, 16965196.
18. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003, 64:1250-1257. 10.4088/JCP.v64n1017, 14658976.
19. Chue P, Llorca PM, Duchesne I, Leal A, Rosillon D, Mehnert A. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 2005, 5:266-274.
20. Guy W, . (Ed) ECDEU Assessment Manual for Psychopharmacology 1976, 218-222. Rockville, MD: US Dept of Health Education and Welfare, National Institute of Mental Health, (Ed).
21. Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995, 166:654-659. 10.1192/bjp.166.5.654, 7620753.
22. Taylor DM, Young CL, Mace S, Patel MX. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 2004, 65:1076-1083. 10.4088/JCP.v65n0808, 15323592.
23. De Marinis T, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 2007, 40:257-263. 10.1055/s-2007-992140, 18030649.
24. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand 2007, 116:36-46. 10.1111/j.1600-0447.2006.00980.x, 17559599.
25. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, . Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223. 10.1056/NEJMoa051688, 16172203, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
26. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000, 342:1878-1886. 10.1056/NEJM200006223422506, 10861324.
27. Haro JM, Edgell ET, Novick D, Alonso J, Kennedy L, Jones PB, Ratcliffe M, Breier A. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005, 111:220-231. 10.1111/j.1600-0447.2004.00450.x, 15701107.
28. Moller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005, 20:121-130. 10.1097/00004850-200505000-00001, 15812261.
29. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006, 63:1079-1087. 10.1001/archpsyc.63.10.1079, 17015810.
30. Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, McQuade RD, Nyilas M, Iwamoto T, Crandall DT. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006, 84:77-89. 10.1016/j.schres.2005.12.857, 16483745.